Start triage first, then route to emergency care.
Need urgent help? Start triage first, then route to emergency care.
Roxee Medication Guide
Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.
Veterinary professional?
These are the reference facts Roxee uses on browse cards and quick facts.
Sponsor, product, and application records imported from Animal Drugs @ FDA.
openFDA reaction terms and case summaries are supporting evidence, not proof of causality.
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: Zoetis Inc.
Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.
Induction of general anesthesia. For induction of anesthesia followed by maintenance with an inhalant anesthetic Maintenance of general anesthesia following induction Species commonly shown: Both, Dog, Cat.
Induction of general anesthesia. For induction of anesthesia followed by maintenance with an inhalant anesthetic Maintenance of general anesthesia following induction
Administer by intravenous injection only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. When using ALFAXAN, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.
Top reported reactions (openFDA): Death, Tachycardia, Cardiac arrest, Vocalisation, Vomiting, Paddling.
Choose a pet, confirm current or past, and optionally add reminder notes.
Sign in to save this medication to your pet profile.
Sign in to continueStart here first for the safest next-step summary before the deeper medication detail.
Used for:
Induction of general anesthesia.
Dosing note:
Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.
What to watch for:
When to call the vet:
Regulatory restrictions are shown in Vet View.
What to tell or ask your vet today:
A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.
Roxee has limited cited overview evidence for Alfaxalone; use the official documents and your veterinarian's instructions for product-specific decisions.
32 tracked reaction signals; 32 reported cases; 25 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.
Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.
Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.
Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.
Unsteady walking (ataxia) (1 reports), Loss of appetite (1 reports), Decreased body temperature (1 reports), Decreased blood urea nitrogen (BUN) or creatinine (1 reports), Death (1 reports)
Digestive (2), Skin & allergy (2), Neurologic (2), Behavior (3)
Cat (19 reports), Dog (13 reports)
Domestic Shorthair (2), Maine Coon (1), Chihuahua (1), ['Siberian', 'Crossbred Feline/cat'] (1). These are report metadata, not proof that a breed is at higher risk.
Verify whether Alfaxalone fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.
Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.
Administer by intravenous injection only, When using ALFAXAN, patients should be continuously monitored, and facilities for the maintenance of, wobbly/unsteady walking, Loss of appetite, Decreased body temperature
Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.
Review status / Updated / Sources
Review status: Clinical reviewer not listed
Updated: February 12, 2026, 10:44 PM UTC
Side effects to monitor:
Most reported reactions:
Emergency warning signs:
Source-backed clinical checkpoints for quick review.
Official label facts first, then secondary summaries. Marketing content is separated below.
Administer by intravenous injection only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. When using ALFAXAN, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.
Received 2026-03-16 · MSK · MSK
Received 2026-01-29 · MSK · MSK
Received 2026-01-16 · MSK · MSK
Received 2025-12-01 · MSK · MSK
Received 2025-12-01 · MSK · MSK
Tap or hover a reaction to see what it means in plain language.
| Reaction | Body system | Cases | Species | Serious cases |
|---|---|---|---|---|
| Neurologic | 1 | Cat | 1 | |
| Digestive | 1 | Cat | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Cat | 1 | |
| Neurologic | 1 | Dog | 1 |
Species coverage: Cat (19) Dog (13)
| Reaction | Body system | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|---|
| Neurologic | Cat | Serious | - | 1 | |
| Digestive | Cat | Serious | - | 1 | |
| Skin & allergy | Cat | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Neurologic | Dog | Serious | - | 1 | |
| Behavior | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Digestive | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Behavior | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Skin & allergy | Cat | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Behavior | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 |
The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.
Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.
Full source previews and metadata remain in the veterinary/professional layer.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
SPL · Structured Product Label
FOI · FOI
FOI · FOI
FOI · FOI
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
Quick facts and links to official labeling and safety signals.
Diagnosis-code mappings are not available for this medication yet.
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 49480-003-01 | 49480 | - | |
| 49480-003-02 | 49480 | - | |
| 54771-6696-1 | 54771 | - | |
| 54771-6696-2 | 54771 | - | |
| 54771-6698-1 | 54771 | - | |
| 54771-6698-2 | 54771 | - |
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
Every non-trivial field is expected to include provenance and update timestamps.
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
Alfaxan® Multidose
RX
Alfaxalone
Injectable Solution
• Intravenous
|
Zoetis Inc. | NADA 141-342 | Approved | Apr 29, 2026 |
Data source: FDA Animal Drugs @ FDA (public search export).
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
FDA page: Open in Animal Drugs @ FDA
Induction of general anesthesia. For induction of anesthesia followed by maintenance with an inhalant anesthetic Maintenance of general anesthesia following induction
Source: FDA Animal Drugs @ FDA • Reference
Administer by intravenous injection only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. When using ALFAXAN, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.
De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).
Showing top 5 for Digestive.
Showing top 5 for Skin & allergy.
Showing top 5 for Neurologic.
Showing top 5 for Behavior.
Showing top 5 for Other.
Data source: FDA openFDA Animal & Veterinary adverse event reports.
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Cat, Domestic Shorthair, Female, 11 year, 3.992 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 0.50 mL per animal • Reactions: Facial pruritus, Medication error NOS • Outcome: Recovered/Normal
Cat, Domestic Shorthair, Male, 7.58 year, 6.98 kilogram • Drug: MSK, Unknown • Reactions: Application site hair loss • Outcome: Ongoing
Cat, Maine Coon, Male, 3 year, 8.591 kilogram • Drug: MSK, Solution, Intravenous, Dose: 2 mL per animal • Reactions: Opisthotonus, Horizontal nystagmus, Prolonged anaesthesia, Intentional misuse • Outcome: Recovered/Normal
Dog, Chihuahua, Female, 8.25 year, 2.54 kilogram • Drug: MSK, Solution, Intravenous, Dose: 0.30 mL per animal • Reactions: Muscle tremor, Opisthotonus, Rigidity of limbs, Star-gazing, Prolonged anaesthesia… • Outcome: Recovered/Normal
Cat, ['Siberian', 'Crossbred Feline/cat'], Female, 4.83 year, 4.85 kilogram • Drug: MSK, Parenteral • Reactions: Application site discharge NOS, Application site reddening, Application site hair loss, Application site lesion • Outcome: Ongoing
Cat, Domestic Mediumhair, Male, 12 year, 4.037 kilogram • Drug: MSK, Solution, Intravenous, Dose: 0.50 mL per animal • Reactions: Horizontal nystagmus, Opisthotonus, Muscle stiffness, Seizure NOS, Intentional misuse • Outcome: Recovered/Normal
Dog, Crossbred Canine/dog, Female, 10 year, 15.876 kilogram • Drug: MSK, Unknown • Reactions: Itching, Licking • Outcome: Ongoing
Dog, Dog (unknown), Male, 8 year, 15.286 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 15 Milligram per animal • Reactions: Lack of efficacy - NOS, Intentional misuse • Outcome: Ongoing
Data source: FDA openFDA Animal & Veterinary adverse event reports.
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.